A Phase II Efficacy and Safety Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).

Condition:   Myelodysplastic Syndromes Interventions:   Drug: MBG453;   Drug: Placebo;   Drug: Hypomethylating agents Sponsor:   Novartis Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials